YU13201A - Sprečavanje proizvodnje sluzi u vazdušnim putevima sa unošenjem egf-r antagonista - Google Patents

Sprečavanje proizvodnje sluzi u vazdušnim putevima sa unošenjem egf-r antagonista

Info

Publication number
YU13201A
YU13201A YU13201A YU13201A YU13201A YU 13201 A YU13201 A YU 13201A YU 13201 A YU13201 A YU 13201A YU 13201 A YU13201 A YU 13201A YU 13201 A YU13201 A YU 13201A
Authority
YU
Yugoslavia
Prior art keywords
egf
administration
antagonist
mucus production
antagonists
Prior art date
Application number
YU13201A
Other languages
English (en)
Inventor
Jay A. Nadel
Kiyoshi Takeyama
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of YU13201A publication Critical patent/YU13201A/sh
Publication of RS50273B publication Critical patent/RS50273B/sr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Abstract

Hiperlučenje sluzi kod pluća je inhbirano sa unošenjem receptora epidermalnog faktora razvoja (EGF-R) antagonista. EGF-R antagonist može da bude u obliku malog organskog molekula, antitela, ili deo antitela koje se vezuje na blokove EGF receptora. EGF-R antagonist se poželjno unosi sa inekcijom u količini dovoljnoj da se formiraju kupaste ćelije u plućnim vezdušnim putevima. Degranulacija kupastih ćelija koja rezultira u proizvodnju sluzi vazdušnog puta je time inhibirana. Takodje su obezbedjeni ogledi za ekranizovanje agenasa kandidata koji inhibiraju proliferaciju kupaste ćelije.[Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
YU13201A 1998-08-18 1999-08-17 Antagonisti receptora epidermalnog faktora rasta za lečenje hipersekrecije mukusa u plućima RS50273B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9702398P 1998-08-18 1998-08-18

Publications (2)

Publication Number Publication Date
YU13201A true YU13201A (sh) 2005-07-19
RS50273B RS50273B (sr) 2009-07-15

Family

ID=22260380

Country Status (36)

Country Link
US (6) US6270747B1 (sh)
EP (2) EP1970058A1 (sh)
JP (2) JP2002539072A (sh)
KR (1) KR100609646B1 (sh)
CN (1) CN1184961C (sh)
AR (1) AR020220A1 (sh)
AT (1) ATE399541T1 (sh)
AU (1) AU760766B2 (sh)
BR (1) BR9912672A (sh)
CA (1) CA2337422C (sh)
CO (1) CO5130028A1 (sh)
CY (1) CY1110370T1 (sh)
CZ (1) CZ2001584A3 (sh)
DE (1) DE69939022D1 (sh)
DK (1) DK1119349T3 (sh)
EA (1) EA004316B1 (sh)
EE (1) EE200100097A (sh)
ES (1) ES2310047T3 (sh)
HK (1) HK1036219A1 (sh)
HR (1) HRP20010119B1 (sh)
HU (1) HUP0103894A3 (sh)
ID (1) ID27345A (sh)
IL (2) IL140855A0 (sh)
MY (1) MY126490A (sh)
NO (1) NO327000B1 (sh)
NZ (1) NZ509271A (sh)
PH (2) PH12010000216A1 (sh)
PL (1) PL200940B1 (sh)
PT (1) PT1119349E (sh)
RS (1) RS50273B (sh)
SI (1) SI1119349T1 (sh)
SK (1) SK287805B6 (sh)
TR (1) TR200100560T2 (sh)
TW (1) TWI250019B (sh)
UA (1) UA73722C2 (sh)
WO (1) WO2000010588A2 (sh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
NZ509271A (en) 1998-08-18 2003-10-31 Univ California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20030236300A1 (en) * 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2003090681A2 (en) * 2002-04-24 2003-11-06 Research Development Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
JP2005535626A (ja) * 2002-06-24 2005-11-24 リサーチ　ディベロップメント　ファンデーション クルクミンによるヒト多発性骨髄腫の治療
US20060241130A1 (en) * 2003-01-31 2006-10-26 Ehud Keinan Anti-inflammatory compositions and uses thereof
US7195899B1 (en) * 2003-03-14 2007-03-27 Florida State University Research Foundation, Inc. Cell-based biosensor for harmful airborne agents
AU2004320907A1 (en) 2003-08-26 2006-04-13 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
CA2536738A1 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
US8846079B1 (en) 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20060115523A1 (en) * 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
DK1687338T3 (da) 2003-11-07 2011-02-07 Ablynx Nv Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
EP1753734A1 (en) * 2004-05-05 2007-02-21 Renopharm Ltd. Nitric oxide donors and uses thereof
US6998028B1 (en) * 2004-09-24 2006-02-14 Superpower, Inc. Methods for forming superconducting conductors
MX2007003608A (es) * 2004-09-27 2007-08-14 Technion Res & Dev Foundation Agentes antimicrobianos novedosos.
US7915223B2 (en) * 2004-09-27 2011-03-29 Technion Research & Development Foundation Ltd. Antimicrobial agents
JP4690158B2 (ja) * 2004-09-28 2011-06-01 スギ生物科学研究所株式会社 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法
US20080072338A1 (en) * 2004-09-28 2008-03-20 Fuji Biomedix Co., Ltd Animal for Drug Efficacy Evaluation, Method for Developing Chronic Obstructive Pulmonary Disease in Animal for Drug Efficacy Evaluation, and Method for Evaluating Drug Efficacy Using the Animal
EP1933624A4 (en) * 2005-10-11 2009-09-16 Univ Washington COMPOSITIONS AND METHOD FOR THE TREATMENT OF HYPERSEKRETION OF RESPIRATORY WAYS
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) * 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2008124496A1 (en) * 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
WO2008132738A2 (en) * 2007-04-30 2008-11-06 Technion Research & Development Foundation Ltd. Anticancerous polymeric agents
US8470770B2 (en) * 2007-04-30 2013-06-25 Technion Research & Development Foundation Ltd. Antimicrobial agents
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP5539351B2 (ja) * 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8734859B1 (en) 2010-11-13 2014-05-27 Sirbal Ltd. Molecular combinations for cancer or other disease treatment
CN103732611B (zh) * 2011-01-10 2016-06-01 伊沃恩有限公司 β-肾上腺素能反向激动剂用于戒烟的用途
ES2703052T3 (es) 2012-08-03 2019-03-06 Cedars Sinai Medical Center Aislamiento de mutantes potenciadores del tráfico de proteína de entrega de fármacos
WO2015082950A1 (en) 2013-12-02 2015-06-11 Sirbal Ltd. Herbal combinations for treatment of a skin condition
WO2017019651A1 (en) 2015-07-29 2017-02-02 Sirbal Ltd. Herbal combinations for treating psoriasis

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932481A (en) * 1954-06-15 1960-04-12 Breer Bipod camera support
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
FR2502627A1 (fr) * 1981-02-02 1982-10-01 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
IT1173549B (it) * 1984-04-02 1987-06-24 Corvi Camillo Spa Estere dell'acido teofillin-7-acetico con il d,l-trans-sobrerolo avente attivita' mucosecretolitica-fluidificante e antibroncospastica, procedimento per la sua preparazione e sue composizioni farmaceutiche
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4904786A (en) * 1986-01-27 1990-02-27 American Home Products Corporation Quinoline compounds as antiallergic and antiinflammatory agents
US5089516A (en) * 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
AU4203789A (en) * 1988-09-28 1990-04-18 Upjohn Company, The 1,4-dihydrothionapthoquinone and heterocyclic congeners which inhibit lipoxygenase enzymes
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8904009D0 (en) 1989-02-22 1989-04-05 Celltech Ltd Vector
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
US5116616A (en) * 1991-04-29 1992-05-26 Bio-Technology General Corp. Use of intratracheal administration of SOD to protect humans from lung injury due to hyperoxia and hyperventilation
DE4117078A1 (de) 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
DE4310051A1 (de) 1992-04-11 1993-10-14 Byk Gulden Lomberg Chem Fab Weitere Verwendung substituierter Pyridazine
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
AU4851393A (en) * 1992-09-11 1994-04-12 Regents Of The University Of Michigan, The Non-human animal with xenograft of on airway populated by human cells
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
AU7623194A (en) 1993-09-03 1995-03-22 Vpi Holdings Ltd. Oligonucleotides with rna cleavage activity
ES2123818T3 (es) * 1993-09-13 1999-01-16 Merck Frosst Canada Inc Procedimiento para medir las variaciones metaplasicas de los epitelocitos mucosecretores.
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
EP0746614A1 (en) 1994-02-23 1996-12-11 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US20030114379A1 (en) * 1994-03-08 2003-06-19 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP0824525B1 (en) 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
DE69710712T3 (de) * 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
ATE280496T1 (de) * 1996-07-29 2004-11-15 Paringenix Inc Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
CA2322311C (en) * 1998-03-04 2009-10-13 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
NZ509271A (en) 1998-08-18 2003-10-31 Univ California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
SK12112001A3 (sk) 1999-02-27 2001-12-03 Boehringer Ingelheim Pharma Kg 4-amino-chinazolínové a chinolínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
TR200201051T2 (tr) * 1999-10-19 2002-09-23 Merck & Co., Inc. Tirosin kinaz inhibitörleri.
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
ES2280375T3 (es) 2000-04-08 2007-09-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Heterociclos biciclicos, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparacion.

Also Published As

Publication number Publication date
DE69939022D1 (de) 2008-08-14
CZ2001584A3 (cs) 2002-06-12
BR9912672A (pt) 2002-06-11
HUP0103894A3 (en) 2003-07-28
SK2162001A3 (en) 2002-08-06
EP1119349B1 (en) 2008-07-02
US6551989B2 (en) 2003-04-22
AR020220A1 (es) 2002-05-02
WO2000010588A3 (en) 2001-05-25
US20010041178A1 (en) 2001-11-15
WO2000010588A9 (en) 2000-08-10
US6270747B1 (en) 2001-08-07
CA2337422C (en) 2010-11-02
AU5676699A (en) 2000-03-14
CO5130028A1 (es) 2002-02-27
US8071074B2 (en) 2011-12-06
NO327000B1 (no) 2009-03-30
PH12010000216A1 (en) 2015-07-27
ID27345A (id) 2001-04-05
IL140855A0 (en) 2002-02-10
ATE399541T1 (de) 2008-07-15
CN1354657A (zh) 2002-06-19
NO20010749D0 (no) 2001-02-14
NO20010749L (no) 2001-04-17
KR100609646B1 (ko) 2006-08-04
US8048844B1 (en) 2011-11-01
PL200940B1 (pl) 2009-02-27
CN1184961C (zh) 2005-01-19
US7358222B2 (en) 2008-04-15
PH12010000215A1 (en) 2015-07-27
TR200100560T2 (tr) 2002-05-21
UA73722C2 (en) 2005-09-15
JP2002539072A (ja) 2002-11-19
CY1110370T1 (el) 2015-04-29
AU760766B2 (en) 2003-05-22
CA2337422A1 (en) 2000-03-02
EA200100136A1 (ru) 2001-10-22
RS50273B (sr) 2009-07-15
HRP20010119A2 (en) 2002-02-28
WO2000010588A2 (en) 2000-03-02
IL140855A (en) 2011-02-28
SK287805B6 (sk) 2011-10-04
EE200100097A (et) 2002-06-17
ES2310047T3 (es) 2008-12-16
TWI250019B (en) 2006-03-01
US20080175797A1 (en) 2008-07-24
HUP0103894A2 (hu) 2002-04-29
PL351765A1 (en) 2003-06-16
EA004316B1 (ru) 2004-02-26
US20030148990A1 (en) 2003-08-07
US20010036919A1 (en) 2001-11-01
EP1119349A2 (en) 2001-08-01
NZ509271A (en) 2003-10-31
PT1119349E (pt) 2008-10-14
KR20010085412A (ko) 2001-09-07
HK1036219A1 (en) 2001-12-28
SI1119349T1 (sl) 2008-12-31
JP2009221212A (ja) 2009-10-01
US6566324B2 (en) 2003-05-20
DK1119349T3 (da) 2008-10-13
MY126490A (en) 2006-10-31
EP1970058A1 (en) 2008-09-17
HRP20010119B1 (en) 2008-05-31

Similar Documents

Publication Publication Date Title
YU13201A (sh) Sprečavanje proizvodnje sluzi u vazdušnim putevima sa unošenjem egf-r antagonista
WO2002005842A3 (en) Preventing airway mucus production by administration of egf-r antagonists
EP1762236A3 (en) Formulations of alpha adrenergic receptor antagonists and their uses
Centrella et al. Isoform-specific regulation of platelet-derived growth factor activity and binding in osteoblast-enriched cultures from fetal rat bone.
GEP20074144B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
MY129348A (en) Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
NZ515464A (en) Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
MXPA01012882A (es) Composiciones y metodos que comprenden gluconato de morfina.
DK1427297T3 (da) Appetitnedsættende procyanidin-holdigt præparat til pattedyr
Kazmi et al. Opioid receptors in human neuroblastoma SH-SY5Y cells: evidence for distinct morphine (μ) and enkephalin (δ) binding sites
BR0109958A (pt) Análogos de didemnina e tamandarina e métodos de preparação e uso deles
NO20050113L (no) Sekundaere amino-aniliniske piperidiner som MCH1-antagonister og anvendelser derav
Eppstein et al. Inhibition of epidermal growth factor/transforming growth factor‐α–stimulated cell growth by a synthetic peptide
DE69739869D1 (de) Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation
Kitaoka et al. Stimulation of FSH release by erythroid differentiation factor (EDF)
Weir et al. In vitro adenylate cyclase-stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice.
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
Suzuki et al. Changes in muscarinic acetylcholine receptors in guinea-pig lung: Effects of aging, inhalation of an allergen, administration of drugs, and vagotomy
Webber et al. The effect of substance P and related peptides on the guinea-pig lung strip
Riopelle et al. Nerve growth factor receptors of human tumors of neural crest origin: characterization of binding site heterogeneity and alteration by theophylline
ES2013408A6 (es) Un metodo para preparar por biotecnologia polipeptidos que tienen actividad de factor de crecimiento.
CN108286306A (zh) 一种卯榫式膨石砌块及其组合墙
EP0344979A3 (en) Alfa-adrenergic receptor antagonists
ES8707741A1 (es) Un procedimiento para prepara un polipeptido que tiene actividad de factor de crecimiento